CpG DNA induces stronger immune responses with less toxicity than other adjuvants

Vaccine

Volumn 18, Issue 17, 2000, Pages 1755-1762

  Weeratna, Risini D ^a   McCluskie, Michael J ^a   Xu, Yu ^a,b   Davis, Heather L ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PFIZER INC   (United States)

Author keywords

Adjuvant; CpG DNA; Vaccines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG DNA; FREUND ADJUVANT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE; PHOSPHORYL LIPID A; TITERMAX GOLD; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CPG ISLAND; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMORAL IMMUNITY; INJECTION SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; TH1 CELL; TH2 CELL; TIBIALIS ANTERIOR MUSCLE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; CPG ISLANDS; DNA; FEMALE; FREUND'S ADJUVANT; HEPATITIS B SURFACE ANTIGENS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; POLOXALENE; TH1 CELLS; TH2 CELLS;

EID: 0033997899     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00526-5     Document Type: Article

References (30)

1. Bomford R. Will adjuvants be needed for vaccines of the future? Dev Biol Stand. 92:1998;13-17.
2. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA. 95:1998;15553-15558.
3. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
4. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 17:1999;255-281.
5. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., Trezza R.P., Heinzel F.P., Forsthuber T., Lehmann P.V. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:1999;3942-3949.
6. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., Krieg A.M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:1998;2555-2559.
7. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
8. Krieg A.M. The CpG motif: implication for clinical immunology. BioDrugs. 10:1998;341-346.
9. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subset. J. Exp. Med. 169:1989;59-72.
10. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10:1992;385-409.
11. Sher A. Schistosomiasis. Parasitizing the cytokine system. Nature. 16:1992;565-566.
12. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:1995;29-60.
13. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., Vandepapeliere P., Slaoui M., Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 16:1998;708-714.
14. Krieg A.M. CpG DNA: a novel immunomodulator. Trends Microbiol. 7:1999;64-65.
15. Broderson J.R. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab. Anim. Sci. 39:1989;400-405.
16. Toth L.A., Dunlap A.W., Olson G.A., Hessler J.R. An evaluation of distress following intraperitoneal immunization with Freund's adjuvant in mice. Lab. Anim. Sci. 39:1989;122-126.
17. Wiedemann F., Link R., Pumpe K., Jacobshagen U., Schaefer H.E., Wiesmuller K.H., Hummel R.P., Jung G., Bessler W., Boltz T. Histopathological studies on the local reactions induced by complete Freund's adjuvant (FCA), bacterial lipoplysaccharides (LPS), and synthetic lipopeptide (P3C) conjugates. J. Pathol. 164:1991;265-271.
18. Leenaars P.P., Koedam M.A., Wester P.W., Baumans V., Claassen E., Hendriksen C.F. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab. Anim. 32:1998;387-406.
19. Leenaars M., Koedam M.A., Hendriksen C.F., Claassen E. Immune responses and side effects of five different oil-based adjuvants in mice. Vet. Immunol. Immunopathol. 61:1998;291-304.
20. Yi A.K., Tuetken R., Redford T., Waldschmidt M., Kirsch J., Krieg A.M. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160:1998;4755-4761.
21. Gustafson G.L., Rhodes M.J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143:1992;483-488.
22. Cookson W.O., Moffatt M.F. Asthma: an epidemic in the absence of infection? Science. 275:1997;41-42.
23. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883.
24. Carson D.A., Raz E. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186:1997;1621-1622.
25. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
26. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:1998;4463-4466.
27. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845.
28. Iho S., Yamamoto T., Takahashi T., Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J. Immunol. 163:1999;3642-3652.
29. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligonucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol. 29:1999;2344-2353.
30. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17:1999;255-281.